Title Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: a Prospective Registry with Central Echocardiography Analysis.

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

The issue of valve durability has become one of the most important aspects in the TAVR field in recent years since transcatheter aortic valve replacement has been progressively applied to younger patients with a low co-morbidity burden. The SAPIEN 3 Ultra RESILIA valve represents the last generation of the SAPIEN valve system and includes several important iterations (newer leaflet calcium-blocking technology targeting calcium-attracting free aldehydes, dry tissue storage, newer skirt textile design) that should translate into a favorable impact on valve durability at mid- to long- term follow-up

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Inclusion criteria - Patients with severe aortic stenosis undergoing transarterial TAVR with the SAPIEN 3 Ultra RESILIA valve.

• Successful valve implantation of the SAPIEN 3 Ultra RESILIA valve.

⁃ VARC-3- defined technical success defined as:

• Freedom from mortality

• Successful access, delivery of the device, and retrieval of the delivery system

• Correct positioning of a single prosthetic heart valve into the proper anatomical location

• Freedom from surgery or intervention related to the device (excluding permanent pacemaker) or to a major vascular or access related, or cardiac structural complication - Absence of severe procedural or in-hospital complications (VARC-3 definitions): mortality, stroke, bleeding type 2-4, myocardial infarction, need for a second valve, valve embolization, coronary obstruction, annular rupture.

Locations
Other Locations
Canada
IUCPQ
RECRUITING
Québec
Contact Information
Primary
Josep Rodés-Cabau, MD
josep.rodes@criucpq.ulaval.ca
4186568711
Backup
Emilie Pelletier beaumont, MSc
emilie.pelletier-beaumont@criucpq.ulaval.ca
418-656-8711
Time Frame
Start Date: 2024-05-16
Estimated Completion Date: 2034-09-01
Participants
Target number of participants: 150
Sponsors
Leads: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

This content was sourced from clinicaltrials.gov